42 results about "Echovirus" patented technology

The invention discloses a programmed multi-target tree-shaped macromolecular assembled body medicine conveying system as well as a preparation method and application thereof and belongs to the field of biomedical materials. The medicine conveying system taking an amphipathic tree-shaped macromolecular assembled body as a carrier is used for realizing programmed multi-target through responding a tumor micro-environment, so that main biological obstacles met in a process of transferring the medicine carrier in a body are overcome, and finally, medicines are conveyed to the destination. The obtained self-assembled body has a multi-target effect through the functionalization effect of a plurality of types of terminal groups. On one hand, tree-shaped molecules are used as the medicine carrier and have the advantages of good stability, high mechanical strength, multivalent terminal groups, hyper-branched structures, and intracellular conveying of echoviruses; on the other hand, a multi-element cooperated self-assembling policy is integrated with the advantages of all functional groups on a tree-shaped macromolecular self-assembled unit, so that the assembled body can be conveyed by the multifunctional and efficient medicine system. The system is particularly suitable for conveying anti-tumor medicines.

The invention relates to a hand-foot-and-mouth disease resistant human immunoglobulin, and preparation and using methods and application thereof in pharmacy. The preparation method comprises the following steps of: separating component I+II+III, I+III and II precipitates in turn by using a low-temperature methanol protein separation method; performing pasteurization on a component II precipitate; refining and purifying; performing dealcholization; preparing; and sterilizing, packaging and performing low-pH incubated inactivation. The product has antibody titer of not less than 1:640 for enteroviruses (including one or more of coxsackie virus, Echo and EV71), the immunoglobulin content is not less than 95.0 percent of the total protein content, and the sum of IgG monomer and dimer is not less than 95 percent; and the using method is that a specific antibody with titer of 160,000-320,000 is intravenously infused. The invention is suitable for industrial production; and the product has high-titer enterovirus resistant specificity, is safe and reliable, and can become an effective medicine for treating the hand-foot-and-mouth disease.

The invention discloses new application of scullcapflavone in preparing a medicament for treating enterovirus infection, in particular new application of scullcapflavone in preparing a medicament for treating or preventing a hand-foot-and-mouth disease caused by enterovirus infection. The scullcapflavone comprises an extract of baicalein, baicalin or scutellaria baicalensis general flavone; and the enterovirus indicates a coxsackie virus A group, a coxsackie virus B group, echovirus or enterovirus EV71 which causes the hand-foot-and-mouth disease. The scullcapflavone as an active substance is mixed with a pharmaceutically allowable excipient and made into a preparation which can be accepted by a patient and can be used for treating and preventing the hand-foot-and-mouth disease by injection administration, mucosa administration, oral administration or inhalation and has obvious treating effect and high safety.

The invention discloses a traditional Chinese medicine composition for treating viral respiratory tract infection and a preparation method thereof. The composition comprises the following raw medicinal materials in parts by weight: 3-20 parts of honey-fried ephedra, 3-20 parts of flos farfarae, 5-25 parts of schizonepeta spike, 5-20 parts of radix asteris, 5-15 parts of apricot kernel, 5-20 parts of roasted perilla seed, 3-15 parts of rhizoma anemarrhenae, 3-15 parts of bulbus fritillariae thunbergii, 5-25 parts of fructus arctii, and 2-15 parts of liquorice. The raw medicinal materials are matched with auxiliary materials and a flavoring agent to be directly or indirectly made into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of dosage forms via conventional processes. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, hand, foot and mouth virus, adenovirus, parainfluenza virus, echovirus, coxsackievirus and the like.

The invention discloses a siRNA echovirus delivery system with a shell-core structure. The core of the structure refers to polyarginine-modified or polyhistidine-modified chitosan coated siRNA, and the shell refers to albumin modified by polypeptide containing an RGD group sequence and by arginine. The delivery system can recognize tumor cells in a targeted mode, after the system enters in an endosome-lysosome acid environment, the protein shell is removed, the exposed core can escape from the endosome-lysosome, and under the intracellular GSH reduction condition, siRNA is released. The delivery system is good in stability, high in gene loading capacity and excellent in active target performance, and can significantly improve the gene silencing effect of siRNA and effectively inhibit the growth and metastasis of tumor cells.

The invention discloses application of cynaroside to preparation of a medicine for treating or preventing hand-foot-and-mouth diseases. The hand-foot-and-mouth diseases are caused by an enterovirus type 71, a type 16, type 4, type 5, type 7, type 9 and type 10 of a coxsackie virus group A, a type 2 and type 5 of a coxsackie virus group B or an echovirus. The medicine takes the cynaroside as an active component and is mixed with a pharmaceutically acceptable auxiliary material to prepare any one clinically acceptable dosage form. The application disclosed by the invention provides a new way for treating the hand-foot-and-mouth diseases; the cynaroside can be developed as a new medicine for preventing the hand-foot-and-mouth diseases; the toxic and side effects are small; the lesion of infected cells is inhibited, a dose-dependent effect is realized and the medicine is a broad-spectrum antiviral medicine; virus replication is inhibited, the virus load in host cells is reduced and viruses are promoted to become negative; the case fatality rate is reduced or eliminated and the survival time of illness cases is prolonged; the content of cell factors is reduced and inflammations caused by virus infection is alleviated; a plurality of administration manners are provided and the medicine can be administrated by injection and can also be orally taken.

The invention discloses a traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of tatarian aster root, 5-25g of Chinese thorowax root, 5-25g of schizonepeta spike, 5-25g of great burdock achene, 5-25g of apricot seed and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, enteric cytopathogenichuman orphan virus, Coxsackie virus and the like.

The invention discloses an enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope, a fusion protein of the enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope and a preparation method and use of the fusion protein and relates to the field of a gene engineering technology, a vaccine and a diagnostic reagent. The preparation method comprises analyzing an enteric cytopathogenic human orphan virus 6-type surface protein VP1 amino acid sequence by a computer, and screening strong specific epitope-containing protein fragments comprising 75th-101th amino acids, 127th-141th amino acids, 204th-237th amino acids and 257th-289th amino acids, wherein the four protein fragments are connected by 2 glycines and 1 serine so that the epitope fusion protein is formed. A codon in favor with eucaryotes and prokaryotes is used, a brand new gene sequence of the epitope fusion protein is chemically synthesized, through a gene engineering technology, the enteric cytopathogenic human orphan virus 6-type VP1 protein epitope fusion protein is expressed and prepared and is used for development of an enteric cytopathogenic human orphan virus antibody detection reagent and preparation of an enteric cytopathogenic human orphan virus monoclonal antibody and polyclonal antibody.

New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided.

The invention discloses antitumor application of echo viruses used as oncolytic viruses. The antitumor application particularly includes application of the echo viruses ECHO1, ECHO3, ECHO4, ECHO5, ECHO6, ECHO7, ECHO9, ECHO11 and ECHO25 to lung cancer, colon cancer, prostate cancer, gastric cancer, liver cancer, pancreatic cancer and rhabdomyoma. The antitumor application has the advantages that different levels of oncolytic activity of the different echo viruses for different types of tumor cells are proved, and accordingly the fact that the echo viruses can be used for specifically treating tumor is prompted.

The invention discloses preparation and application of an echovirus type 1 VP1 protein specific antigen epitope and a fusion protein thereof, and relates to the fields of gene engineering technology, vaccines and diagnostic reagents. An amino acid sequence of the echovirus type 1 surface protein VP1 is analyzed by a computer, and protein fragments, namely a protein fragment from a 75th amino acid to a 140th amino acid and a protein fragment from a 203rd amino acid to a 236th amino acid, containing strong specific antigen epitopes are screened; the two protein fragments are connected by two glycines and one serine, and the antigen epitope fusion protein is formed. Codons preferred by eukaryotes and prokaryotes are selected, and the bran-new gene sequence of the antigen epitope fusion protein is chemically synthesized; with use of the genetic engineering technology, the echovirus type 1 VP1 protein antigen epitope fusion protein is expressed and prepared, is used for development of echovirus antibody detection reagents, and is used for preparation of echovirus monoclonal and polyclonal antibodies.

There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognize α2β1 for infectivity of the cells. There are also provided methods for screening viruses for use in a method of the invention as well as pharmaceutical compositions for use in the methods.

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

The invention relates to the technical field of pathogen detection, in particular to a universal nucleic acid detection reagent for enteroviruses EV71, CA16 and EV. The universal nucleic acid detection reagent for the enteroviruses EV71, CA16 and EV provided by the invention can tolerate interference of inhibitors, namely cholate and haemachrome due to the addition of an anti-inhibition component;and furthermore, the reagent can be stably stored at 2-8 DEG C and avoids the harsh condition of cryopreservation at -20 DEG C, so that unfreezing is not needed before reaction, and the reaction efficiency is improved. The reagent is suitable for more sample types, such as a throat swab, excrement, a herpes fluid and a cloacal swab when prepared into a kit. A universal primer of the kit covers more serotypes, including coxsackie A, coxsackie B, the enterovirus 71 and an echo virus. The kit has good sensitivity, specificity and repeatability.

The invention provides echovirus type-9 VP1 protein specific antigen epitope and a preparation method and application of a fusion protein thereof, and relates to the fields of genetic engineering technology, vaccines and diagnostic reagents. Computer analysis is carried out on the amino acid sequence of the echovirus type-9 surface protein VP1 to screen out protein fragments containing strong specific antigen epitope, namely 75th amino acid-102nd amino acid, 127th amino acid-140th amino acid, 204th amino acid-237th amino acid and 257th amino acid-300th amino acid, and the four protein fragments are connected through two glycines and one serine to form one antigen epitope fusion protein. Codons preferred by both eukaryon and prokaryote are selected for chemical synthesis of a brand new gene sequence of the antigen epitope fusion protein, the genetic engineering technology is utilized to prepare the antigen epitope fusion protein of the echovirus type-9 VP1 protein by expression, and the antigen epitope fusion protein is used for developing an echovirus antibody detection kit and preparing echovirus monoclonal antibody and polyclonal antibody.

The invention discloses an application of epigallocatechin gallate in preparation of a medicine for treating and / or preventing diseases caused by Epidemic diarrhea virus infection. The EGCG in-vitro anti-Erkovirus effect and mechanism are deeply discussed, the feasibility of the EGCG serving as an Erkovirus treatment medicine is verified, a theoretical basis is provided for research and development of natural products of Erkovirus inhibitors, and the product is expected to be used for treating various diseases caused by Erkovirus infection.

The invention relates to the field of virus and the field of tumor treatment. Concretely, the invention relates to ECHO 25 or a modified form thereof, or a genomic sequence or cDNA sequence comprisingthe ECHO 25 or the modified form of the ECHO 25, or nucleic acid molecules of a complementary sequences of the genomic sequence or cDNA sequence, applications in treating tumors for a subject such asa human being, and applications in preparing pharmaceutical compositions for treating the tumors for the subject such as a human being. The invention also relates to a method for treating the tumors.The method includes steps of applying the ECHO 25 or the modified form of the ECHO 25, or the genomic sequence or cDNA sequence comprising the ECHO 25 or the modified form of the ECHO 25 or the nucleic acid molecules of the complementary sequences of the genomic sequence or cDNA sequence to the subject who needs the treatment.

The invention discloses a method for detecting an echovirus type 9 antibody, which takes ECHO9 VP1 recombinant protein as an antigen of an elisa plate, breaks through the limitation that a virus strain is directly inactivated to serve as an antigen to coat the elisa plate in the past or virus strain infected cells are used for preparing an antigen sheet, and meets the requirements of high throughput and safety in preparation of the elisa plate. The kit is beneficial to clinical treatment of sterile encephalitis diseases, and plays an important role in technical support for early discovery and early intervention of sudden epidemic situations caused by ECHO9, epidemiological research and guarantee of health of the masses.

Aqueous solution, cream, hydrogel or spray composition containing compound Sn-On-Xn; where S(n=5-8), O (n=3-7) and X═Fe, Cr or Ni, and most effectively, S7-O4-Fe4 as active ingredient for cutaneous, intradermal and subcutaneous treatment of dermo-epithelial lesions, comprising but not limited to, certain types of skin cancer (basal cell, keratocanthoma and spinocellular carcinomas), conjunctivitis, folliculitis, acne, gingivitis, stomatitis, fungal, dermatomycosis, parasitosis, condylomatosis, balanitis, vaginitis, vaginosis, bacteriosis and endometriosis; by reducing the number of infecting microorganism, not limited to Candida sp., Actinobacillus actinomycetemcomitans, Pseudomonas sp., Porphyromonas gingivalis., Escherichia, sp., Staphyloccocus sp. Streptococcus sp., Herpes simplex I, Herpes simplex II, Coxackievirus A and B, Echovirus, Varicella Zoster (HHV-3), Human Papilloma Virus Gardnerella Vaginalis, Trichomonas vaginalis, Corynebacterium sp., present on the body skin and mucosas. Treating condition may include other abnormal conditions of the skin and epithelium, including insect bites, leukoplakia, oral (aphthous) ulcers and burns, trauma, aphthous, herpervirus infections, stomatitis, herpangina (mouth blisters), a painful mouth infection caused by coxsackieviruses.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The invention provides application of golden flower cold-clearing granules or active ingredients thereof in preparation of medicines for preventing, relieving and / or treating diseases caused by enterovirus infection. The golden flower cold-clearing granules and the effective components of the burdock phenol A and the 5, 7, 3 '-trihydroxy-6, 4', 5 '-trimethoxyflavone have good inhibitory activity on type 1 poliomyelitis virus, coxsackie virus group A type 9, enterovirus type 71, echovirus type 11 and coxsackie virus group B type 3, and the golden flower cold-clearing granules and the effective components of the burdock phenol A and the 5, 7, 3'-trihydroxy-6, 4 ', 5'-trimethoxyflavone have good inhibitory activity on type 1 poliomyelitis virus. Therefore, the golden flower cold-clearing granules or the effective components thereof have important clinical application value in treatment of diseases infected with enteroviruses.

The invention provides application of pepper in preparation of a medicine for treating and / or preventing respiratory virus pneumonia. The invention also discloses a method for effectively inhibiting and / or treating coronavirus, human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, coxsackie virus, echovirus, herpes simplex virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus and herpes zoster virus. The invention provides a new choice for clinical treatment of infection of respiratory viruses such as chicken pox-herpes zoster virus or rhinovirus.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.

The present invention provides methods for determining the presence or absence of enterovirus and parechovirus in a biological sample. The methods involve identifying the presence or absence of target nucleotides from the viruses using amplification directly from the biological sample without a nucleotide extraction step, but substantially maintaining the same specificity and sensitivity as methods that assay extracted nucleotides. Diagnostic methods using the provided methods and compositions and kits for practicing the methods are also provided.

This invention discloses a method for preparing ECHO virus type 30 VP. The method comprises: (1) performing trizol decomposition and extraction of ECHO virus type 30 to obtain VP mRNA, performing reverse transcription to obtain VP cDNA, amplifying by PCR, purifying and cutting with enzyme to obtain Pet41a+VP; (2) transferring to Escherichia coli DH5a, amplifying, extracting and purifying to obtain recombinant plasmid with right sequence; (3) transferring to BL21 (DE3) bacterium, and expressing recombinant protein at 30 deg.C and 0.1mM IPTG; (4) culturing the activated strains of recombinant protein, fermenting at a high density, and inducing in low-oxygen condition, decomposing the bacterium obtained, and dissolving the inclusion body and purifying; (5) inspecting by immunoassay or bioactivity detection, and collecting purified ECHO virus type 30 VP.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention provides application of isoquinoline alkaloid YS-49 in preparation of an anti-echovirus drug, and belongs to the technical field of medical application. Most of the research and development of echovirus drugs and the research of vaccines are designed or modified aiming at viruses, cell physiology is taken as a research object, the influence of the isoquinoline alkaloid YS-49 on virus replication is found through the influence of the isoquinoline alkaloid YS-49 on cellular pathways, and a new thought is provided for the research and development of drugs and vaccines in the future.

The invention discloses new application of scullcapflavone in preparing a medicament for treating enterovirus infection, in particular new application of scullcapflavone in preparing a medicament for treating or preventing a hand-foot-and-mouth disease caused by enterovirus infection. The scullcapflavone comprises an extract of baicalein, baicalin or scutellaria baicalensis general flavone; and the enterovirus indicates a coxsackie virus A group, a coxsackie virus B group, echovirus or enterovirus EV71 which causes the hand-foot-and-mouth disease. The scullcapflavone as an active substance ismixed with a pharmaceutically allowable excipient and made into a preparation which can be accepted by a patient and can be used for treating and preventing the hand-foot-and-mouth disease by injection administration, mucosa administration, oral administration or inhalation and has obvious treating effect and high safety.

The invention provides application of a plant exosome in treatment of nervous system inflammation caused by echovirus, and relates to the technical field of biological medicine, RT-PCR and TCID50 methods are used for detecting the copy number of echovirus nucleic acid and virus virulence in cell supernatant, the antiviral effect of the plant exosome is systematically evaluated, and the result shows that the plant exosome can be used for treating nervous system inflammation caused by echovirus. The plant exosome can effectively reduce the replication or release of the echovirus to play an antiviral role. It is verified that the PE-G can significantly improve the survival rate of nerve cells, especially under high-concentration treatment, the cell survival rate is improved most obviously, the replication of echovirus and the level of inflammatory factors are reduced, and it is indicated that the PE-G has good antiviral and anti-inflammatory effects. The invention provides a novel potential strategy for treating nervous system inflammation caused by the echovirus, also provides key theoretical and data support for clinical transformation application of the plant exosome, and has important scientific value and clinical significance and wide clinical application prospect.